The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

So, TMK; Cakaloglu, Y; Gerken, G; Simon, C; Janssen, HLA; van Zonneveld, M; Flink, HJ; Verhey, E; Senturk, H; Zeuzem, S; Akarca, US; Schalm, SW; Hansen, BE; de Man, RA

Date

2005

Author

So, TMK

Cakaloglu, Y

Gerken, G

Simon, C

Janssen, HLA

van Zonneveld, M

Flink, HJ

Verhey, E

Senturk, H

Zeuzem, S

Akarca, US

Schalm, SW

Hansen, BE

de Man, RA

Metadata

Show full item record

Abstract

Background: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events.

URI

http://hdl.handle.net/20.500.12627/13877
https://doi.org/10.1111/j.1365-2036.2005.02453.x

Collections

Makale [92796]